Bill

Bill > HR2148


US HR2148

US HR2148
Prescription Drug Price Relief Act of 2021


summary

Introduced
03/23/2021
In Committee
10/19/2021
Crossed Over
Passed
Dead
01/03/2023

Introduced Session

117th Congress

Bill Summary

A BILL To significantly lower prescription drug prices for patients in the United States by ending government-granted mo- nopolies for manufacturers who charge drug prices that are higher than the median prices at which the drugs are available in other countries.

AI Summary

This bill, the Prescription Drug Price Relief Act of 2021, aims to significantly lower prescription drug prices in the United States by ending government-granted monopolies for manufacturers who charge drug prices that are higher than the median prices in five reference countries (Canada, the United Kingdom, Germany, France, and Japan). The Secretary of Health and Human Services would determine which brand name drugs have excessive prices and would then waive or void any government-granted exclusivities for those drugs, allowing for the issuance of open, non-exclusive licenses to any person to make, use, or sell those drugs. The bill also includes provisions for expedited review of generic drug and biosimilar applications, civil penalties for non-compliant manufacturers, and a public database of excessive drug price determinations.

Committee Categories

Business and Industry, Government Affairs, Health and Social Services

Sponsors (19)

Last Action

Referred to the Subcommittee on Antitrust, Commercial, and Administrative Law. (on 10/19/2021)

bill text


bill summary

Loading...

bill summary

Loading...
Loading...